nodes	percent_of_prediction	percent_of_DWPC	metapath
Abiraterone—prostate cancer—urinary bladder cancer	0.666	1	CtDrD
Abiraterone—ABCC1—Epirubicin—urinary bladder cancer	0.0411	0.207	CbGbCtD
Abiraterone—ABCC1—Etoposide—urinary bladder cancer	0.032	0.161	CbGbCtD
Abiraterone—ABCC1—Doxorubicin—urinary bladder cancer	0.0218	0.11	CbGbCtD
Abiraterone—ABCC1—Methotrexate—urinary bladder cancer	0.0212	0.107	CbGbCtD
Abiraterone—ALB—Fluorouracil—urinary bladder cancer	0.0177	0.0892	CbGbCtD
Abiraterone—CYP3A4—Thiotepa—urinary bladder cancer	0.0171	0.086	CbGbCtD
Abiraterone—CYP2C8—Fluorouracil—urinary bladder cancer	0.0137	0.0689	CbGbCtD
Abiraterone—CYP2C8—Etoposide—urinary bladder cancer	0.0114	0.0575	CbGbCtD
Abiraterone—ALB—Methotrexate—urinary bladder cancer	0.00976	0.0492	CbGbCtD
Abiraterone—CYP2D6—Doxorubicin—urinary bladder cancer	0.00497	0.025	CbGbCtD
Abiraterone—CYP3A4—Etoposide—urinary bladder cancer	0.00463	0.0233	CbGbCtD
Abiraterone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00316	0.0159	CbGbCtD
Abiraterone—SULT2A1—prostate gland—urinary bladder cancer	0.00303	0.19	CbGeAlD
Abiraterone—SULT2A1—female reproductive system—urinary bladder cancer	0.00166	0.104	CbGeAlD
Abiraterone—CYP3A4—urine—urinary bladder cancer	0.00108	0.0674	CbGeAlD
Abiraterone—CYP2D6—urine—urinary bladder cancer	0.00106	0.0663	CbGeAlD
Abiraterone—SULT2A1—lymph node—urinary bladder cancer	0.000969	0.0606	CbGeAlD
Abiraterone—ORM1—prostate gland—urinary bladder cancer	0.000927	0.058	CbGeAlD
Abiraterone—CYP17A1—renal system—urinary bladder cancer	0.0009	0.0563	CbGeAlD
Abiraterone—CYP17A1—female reproductive system—urinary bladder cancer	0.000721	0.0451	CbGeAlD
Abiraterone—ABCC1—prostate gland—urinary bladder cancer	0.000671	0.042	CbGeAlD
Abiraterone—ABCC1—seminal vesicle—urinary bladder cancer	0.000568	0.0355	CbGeAlD
Abiraterone—ORM1—female reproductive system—urinary bladder cancer	0.000506	0.0317	CbGeAlD
Abiraterone—ABCC1—urethra—urinary bladder cancer	0.000449	0.0281	CbGeAlD
Abiraterone—CYP17A1—lymph node—urinary bladder cancer	0.000422	0.0264	CbGeAlD
Abiraterone—CYP2C8—renal system—urinary bladder cancer	0.000389	0.0244	CbGeAlD
Abiraterone—ABCC1—vagina—urinary bladder cancer	0.000331	0.0207	CbGeAlD
Abiraterone—CYP2C8—female reproductive system—urinary bladder cancer	0.000312	0.0195	CbGeAlD
Abiraterone—ORM1—lymph node—urinary bladder cancer	0.000296	0.0185	CbGeAlD
Abiraterone—CYP2C8—vagina—urinary bladder cancer	0.000282	0.0176	CbGeAlD
Abiraterone—CYP3A4—renal system—urinary bladder cancer	0.000264	0.0165	CbGeAlD
Abiraterone—ALB—lymph node—urinary bladder cancer	0.00026	0.0162	CbGeAlD
Abiraterone—CYP2D6—renal system—urinary bladder cancer	0.00026	0.0162	CbGeAlD
Abiraterone—ABCC1—lymph node—urinary bladder cancer	0.000214	0.0134	CbGeAlD
Abiraterone—Rash—Mitomycin—urinary bladder cancer	0.000214	0.00342	CcSEcCtD
Abiraterone—Dermatitis—Mitomycin—urinary bladder cancer	0.000213	0.00342	CcSEcCtD
Abiraterone—CYP3A4—female reproductive system—urinary bladder cancer	0.000211	0.0132	CbGeAlD
Abiraterone—Mental disorder—Thiotepa—urinary bladder cancer	0.00021	0.00336	CcSEcCtD
Abiraterone—CYP2D6—female reproductive system—urinary bladder cancer	0.000208	0.013	CbGeAlD
Abiraterone—Nocturia—Epirubicin—urinary bladder cancer	0.000207	0.00332	CcSEcCtD
Abiraterone—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.000206	0.0033	CcSEcCtD
Abiraterone—Myocardial infarction—Cisplatin—urinary bladder cancer	0.000205	0.00329	CcSEcCtD
Abiraterone—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000199	0.00319	CcSEcCtD
Abiraterone—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000198	0.00317	CcSEcCtD
Abiraterone—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000198	0.00316	CcSEcCtD
Abiraterone—Pneumonia—Etoposide—urinary bladder cancer	0.000193	0.00309	CcSEcCtD
Abiraterone—Anaemia—Thiotepa—urinary bladder cancer	0.000193	0.00309	CcSEcCtD
Abiraterone—Phosphatase alkaline increased—Epirubicin—urinary bladder cancer	0.000192	0.00308	CcSEcCtD
Abiraterone—Infestation—Etoposide—urinary bladder cancer	0.000192	0.00307	CcSEcCtD
Abiraterone—Infestation NOS—Etoposide—urinary bladder cancer	0.000192	0.00307	CcSEcCtD
Abiraterone—Nocturia—Doxorubicin—urinary bladder cancer	0.000192	0.00307	CcSEcCtD
Abiraterone—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.000189	0.00303	CcSEcCtD
Abiraterone—Myocardial infarction—Etoposide—urinary bladder cancer	0.000188	0.00301	CcSEcCtD
Abiraterone—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.000187	0.003	CcSEcCtD
Abiraterone—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000186	0.00297	CcSEcCtD
Abiraterone—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000185	0.00296	CcSEcCtD
Abiraterone—Urethral disorder—Cisplatin—urinary bladder cancer	0.000184	0.00295	CcSEcCtD
Abiraterone—Angiopathy—Gemcitabine—urinary bladder cancer	0.000183	0.00293	CcSEcCtD
Abiraterone—Fluid retention—Epirubicin—urinary bladder cancer	0.000183	0.00292	CcSEcCtD
Abiraterone—Cough—Thiotepa—urinary bladder cancer	0.000182	0.00292	CcSEcCtD
Abiraterone—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.000182	0.00291	CcSEcCtD
Abiraterone—Hypertension—Thiotepa—urinary bladder cancer	0.00018	0.00288	CcSEcCtD
Abiraterone—Arrhythmia—Gemcitabine—urinary bladder cancer	0.00018	0.00288	CcSEcCtD
Abiraterone—Phosphatase alkaline increased—Doxorubicin—urinary bladder cancer	0.000178	0.00285	CcSEcCtD
Abiraterone—Myalgia—Thiotepa—urinary bladder cancer	0.000178	0.00284	CcSEcCtD
Abiraterone—Arrhythmia—Fluorouracil—urinary bladder cancer	0.000177	0.00284	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000177	0.00282	CcSEcCtD
Abiraterone—Cardiac disorder—Cisplatin—urinary bladder cancer	0.000175	0.00279	CcSEcCtD
Abiraterone—Urinary tract disorder—Etoposide—urinary bladder cancer	0.00017	0.00272	CcSEcCtD
Abiraterone—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000169	0.00271	CcSEcCtD
Abiraterone—Infection—Thiotepa—urinary bladder cancer	0.000169	0.00271	CcSEcCtD
Abiraterone—Fluid retention—Doxorubicin—urinary bladder cancer	0.000169	0.0027	CcSEcCtD
Abiraterone—Urethral disorder—Etoposide—urinary bladder cancer	0.000169	0.0027	CcSEcCtD
Abiraterone—Arrhythmia—Cisplatin—urinary bladder cancer	0.000168	0.00269	CcSEcCtD
Abiraterone—Skin disorder—Thiotepa—urinary bladder cancer	0.000165	0.00265	CcSEcCtD
Abiraterone—Anaemia—Gemcitabine—urinary bladder cancer	0.000162	0.0026	CcSEcCtD
Abiraterone—Blood alkaline phosphatase increased—Epirubicin—urinary bladder cancer	0.00016	0.00257	CcSEcCtD
Abiraterone—Cardiac disorder—Etoposide—urinary bladder cancer	0.00016	0.00256	CcSEcCtD
Abiraterone—Anaemia—Fluorouracil—urinary bladder cancer	0.00016	0.00255	CcSEcCtD
Abiraterone—Angiopathy—Etoposide—urinary bladder cancer	0.000156	0.0025	CcSEcCtD
Abiraterone—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000155	0.00248	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000155	0.00248	CcSEcCtD
Abiraterone—Cough—Gemcitabine—urinary bladder cancer	0.000153	0.00245	CcSEcCtD
Abiraterone—Hypertension—Gemcitabine—urinary bladder cancer	0.000152	0.00243	CcSEcCtD
Abiraterone—Anaemia—Cisplatin—urinary bladder cancer	0.000151	0.00242	CcSEcCtD
Abiraterone—Dyspepsia—Thiotepa—urinary bladder cancer	0.00015	0.0024	CcSEcCtD
Abiraterone—Chest pain—Gemcitabine—urinary bladder cancer	0.00015	0.00239	CcSEcCtD
Abiraterone—Myalgia—Gemcitabine—urinary bladder cancer	0.00015	0.00239	CcSEcCtD
Abiraterone—Hot flush—Epirubicin—urinary bladder cancer	0.000149	0.00239	CcSEcCtD
Abiraterone—Blood alkaline phosphatase increased—Doxorubicin—urinary bladder cancer	0.000148	0.00238	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000148	0.00238	CcSEcCtD
Abiraterone—Menopausal symptoms—Epirubicin—urinary bladder cancer	0.000148	0.00237	CcSEcCtD
Abiraterone—Discomfort—Gemcitabine—urinary bladder cancer	0.000148	0.00236	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000147	0.00235	CcSEcCtD
Abiraterone—Chest pain—Fluorouracil—urinary bladder cancer	0.000147	0.00235	CcSEcCtD
Abiraterone—Myalgia—Fluorouracil—urinary bladder cancer	0.000147	0.00235	CcSEcCtD
Abiraterone—Fatigue—Thiotepa—urinary bladder cancer	0.000147	0.00235	CcSEcCtD
Abiraterone—Constipation—Thiotepa—urinary bladder cancer	0.000146	0.00233	CcSEcCtD
Abiraterone—Discomfort—Fluorouracil—urinary bladder cancer	0.000145	0.00232	CcSEcCtD
Abiraterone—Oedema—Gemcitabine—urinary bladder cancer	0.000143	0.00229	CcSEcCtD
Abiraterone—Cardiac failure—Epirubicin—urinary bladder cancer	0.000143	0.00229	CcSEcCtD
Abiraterone—Infection—Gemcitabine—urinary bladder cancer	0.000142	0.00228	CcSEcCtD
Abiraterone—Oedema—Fluorouracil—urinary bladder cancer	0.000141	0.00226	CcSEcCtD
Abiraterone—Infection—Fluorouracil—urinary bladder cancer	0.00014	0.00224	CcSEcCtD
Abiraterone—Myalgia—Cisplatin—urinary bladder cancer	0.000139	0.00223	CcSEcCtD
Abiraterone—Skin disorder—Gemcitabine—urinary bladder cancer	0.000139	0.00223	CcSEcCtD
Abiraterone—Anaemia—Etoposide—urinary bladder cancer	0.000139	0.00222	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000138	0.00221	CcSEcCtD
Abiraterone—Hot flush—Doxorubicin—urinary bladder cancer	0.000138	0.00221	CcSEcCtD
Abiraterone—Discomfort—Cisplatin—urinary bladder cancer	0.000138	0.0022	CcSEcCtD
Abiraterone—Menopausal symptoms—Doxorubicin—urinary bladder cancer	0.000137	0.00219	CcSEcCtD
Abiraterone—Body temperature increased—Thiotepa—urinary bladder cancer	0.000135	0.00216	CcSEcCtD
Abiraterone—Oedema—Cisplatin—urinary bladder cancer	0.000134	0.00214	CcSEcCtD
Abiraterone—Infection—Cisplatin—urinary bladder cancer	0.000133	0.00212	CcSEcCtD
Abiraterone—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000132	0.00212	CcSEcCtD
Abiraterone—Cough—Etoposide—urinary bladder cancer	0.000131	0.00209	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000131	0.00209	CcSEcCtD
Abiraterone—Skin disorder—Cisplatin—urinary bladder cancer	0.00013	0.00208	CcSEcCtD
Abiraterone—Insomnia—Gemcitabine—urinary bladder cancer	0.00013	0.00207	CcSEcCtD
Abiraterone—Hypertension—Etoposide—urinary bladder cancer	0.000129	0.00207	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000128	0.00205	CcSEcCtD
Abiraterone—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000128	0.00204	CcSEcCtD
Abiraterone—Chest pain—Etoposide—urinary bladder cancer	0.000128	0.00204	CcSEcCtD
Abiraterone—Insomnia—Fluorouracil—urinary bladder cancer	0.000127	0.00204	CcSEcCtD
Abiraterone—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000127	0.00203	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000127	0.00203	CcSEcCtD
Abiraterone—Discomfort—Etoposide—urinary bladder cancer	0.000126	0.00202	CcSEcCtD
Abiraterone—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000126	0.00201	CcSEcCtD
Abiraterone—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000126	0.00201	CcSEcCtD
Abiraterone—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000125	0.002	CcSEcCtD
Abiraterone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000124	0.00199	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000124	0.00198	CcSEcCtD
Abiraterone—Fatigue—Gemcitabine—urinary bladder cancer	0.000124	0.00198	CcSEcCtD
Abiraterone—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000123	0.00197	CcSEcCtD
Abiraterone—Constipation—Gemcitabine—urinary bladder cancer	0.000123	0.00196	CcSEcCtD
Abiraterone—Asthenia—Thiotepa—urinary bladder cancer	0.000122	0.00196	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000122	0.00195	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000122	0.00195	CcSEcCtD
Abiraterone—Infection—Etoposide—urinary bladder cancer	0.000122	0.00195	CcSEcCtD
Abiraterone—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.00012	0.00192	CcSEcCtD
Abiraterone—Dyspnoea—Cisplatin—urinary bladder cancer	0.000119	0.00191	CcSEcCtD
Abiraterone—Skin disorder—Etoposide—urinary bladder cancer	0.000119	0.0019	CcSEcCtD
Abiraterone—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000118	0.00188	CcSEcCtD
Abiraterone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000117	0.00187	CcSEcCtD
Abiraterone—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000116	0.00186	CcSEcCtD
Abiraterone—Pneumonia—Methotrexate—urinary bladder cancer	0.000116	0.00185	CcSEcCtD
Abiraterone—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000115	0.00185	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000115	0.00185	CcSEcCtD
Abiraterone—Infestation—Methotrexate—urinary bladder cancer	0.000115	0.00184	CcSEcCtD
Abiraterone—Infestation NOS—Methotrexate—urinary bladder cancer	0.000115	0.00184	CcSEcCtD
Abiraterone—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000114	0.00182	CcSEcCtD
Abiraterone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000113	0.00181	CcSEcCtD
Abiraterone—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000112	0.00179	CcSEcCtD
Abiraterone—Pollakiuria—Epirubicin—urinary bladder cancer	0.000111	0.00178	CcSEcCtD
Abiraterone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000111	0.00178	CcSEcCtD
Abiraterone—Haematuria—Methotrexate—urinary bladder cancer	0.00011	0.00175	CcSEcCtD
Abiraterone—Dyspnoea—Etoposide—urinary bladder cancer	0.000109	0.00175	CcSEcCtD
Abiraterone—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000109	0.00174	CcSEcCtD
Abiraterone—Vomiting—Thiotepa—urinary bladder cancer	0.000108	0.00173	CcSEcCtD
Abiraterone—Pneumonia—Epirubicin—urinary bladder cancer	0.000108	0.00173	CcSEcCtD
Abiraterone—Infestation—Epirubicin—urinary bladder cancer	0.000108	0.00172	CcSEcCtD
Abiraterone—Infestation NOS—Epirubicin—urinary bladder cancer	0.000108	0.00172	CcSEcCtD
Abiraterone—Rash—Thiotepa—urinary bladder cancer	0.000107	0.00172	CcSEcCtD
Abiraterone—Dermatitis—Thiotepa—urinary bladder cancer	0.000107	0.00172	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000106	0.00169	CcSEcCtD
Abiraterone—Body temperature increased—Cisplatin—urinary bladder cancer	0.000106	0.00169	CcSEcCtD
Abiraterone—Fatigue—Etoposide—urinary bladder cancer	0.000106	0.00169	CcSEcCtD
Abiraterone—Constipation—Etoposide—urinary bladder cancer	0.000105	0.00167	CcSEcCtD
Abiraterone—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000105	0.00167	CcSEcCtD
Abiraterone—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000104	0.00166	CcSEcCtD
Abiraterone—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000103	0.00165	CcSEcCtD
Abiraterone—Asthenia—Gemcitabine—urinary bladder cancer	0.000103	0.00165	CcSEcCtD
Abiraterone—Haematuria—Epirubicin—urinary bladder cancer	0.000103	0.00164	CcSEcCtD
Abiraterone—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000102	0.00163	CcSEcCtD
Abiraterone—Urethral disorder—Methotrexate—urinary bladder cancer	0.000101	0.00162	CcSEcCtD
Abiraterone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000101	0.00161	CcSEcCtD
Abiraterone—Pneumonia—Doxorubicin—urinary bladder cancer	0.0001	0.0016	CcSEcCtD
Abiraterone—Infestation NOS—Doxorubicin—urinary bladder cancer	9.95e-05	0.00159	CcSEcCtD
Abiraterone—Infestation—Doxorubicin—urinary bladder cancer	9.95e-05	0.00159	CcSEcCtD
Abiraterone—Diarrhoea—Gemcitabine—urinary bladder cancer	9.81e-05	0.00157	CcSEcCtD
Abiraterone—Body temperature increased—Etoposide—urinary bladder cancer	9.67e-05	0.00155	CcSEcCtD
Abiraterone—Urinary tract infection—Doxorubicin—urinary bladder cancer	9.67e-05	0.00155	CcSEcCtD
Abiraterone—Diarrhoea—Fluorouracil—urinary bladder cancer	9.64e-05	0.00154	CcSEcCtD
Abiraterone—Asthenia—Cisplatin—urinary bladder cancer	9.58e-05	0.00153	CcSEcCtD
Abiraterone—Cardiac disorder—Methotrexate—urinary bladder cancer	9.58e-05	0.00153	CcSEcCtD
Abiraterone—Urinary tract disorder—Epirubicin—urinary bladder cancer	9.54e-05	0.00153	CcSEcCtD
Abiraterone—Haematuria—Doxorubicin—urinary bladder cancer	9.49e-05	0.00152	CcSEcCtD
Abiraterone—Connective tissue disorder—Epirubicin—urinary bladder cancer	9.49e-05	0.00152	CcSEcCtD
Abiraterone—Urethral disorder—Epirubicin—urinary bladder cancer	9.47e-05	0.00151	CcSEcCtD
Abiraterone—Angiopathy—Methotrexate—urinary bladder cancer	9.36e-05	0.0015	CcSEcCtD
Abiraterone—Mediastinal disorder—Methotrexate—urinary bladder cancer	9.3e-05	0.00149	CcSEcCtD
Abiraterone—Diarrhoea—Cisplatin—urinary bladder cancer	9.14e-05	0.00146	CcSEcCtD
Abiraterone—Vomiting—Gemcitabine—urinary bladder cancer	9.11e-05	0.00146	CcSEcCtD
Abiraterone—Mental disorder—Methotrexate—urinary bladder cancer	9.04e-05	0.00145	CcSEcCtD
Abiraterone—Rash—Gemcitabine—urinary bladder cancer	9.04e-05	0.00145	CcSEcCtD
Abiraterone—Dermatitis—Gemcitabine—urinary bladder cancer	9.03e-05	0.00144	CcSEcCtD
Abiraterone—Cardiac disorder—Epirubicin—urinary bladder cancer	8.96e-05	0.00143	CcSEcCtD
Abiraterone—Vomiting—Fluorouracil—urinary bladder cancer	8.96e-05	0.00143	CcSEcCtD
Abiraterone—Rash—Fluorouracil—urinary bladder cancer	8.89e-05	0.00142	CcSEcCtD
Abiraterone—Dermatitis—Fluorouracil—urinary bladder cancer	8.88e-05	0.00142	CcSEcCtD
Abiraterone—Urinary tract disorder—Doxorubicin—urinary bladder cancer	8.82e-05	0.00141	CcSEcCtD
Abiraterone—Asthenia—Etoposide—urinary bladder cancer	8.78e-05	0.00141	CcSEcCtD
Abiraterone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	8.78e-05	0.00141	CcSEcCtD
Abiraterone—Angiopathy—Epirubicin—urinary bladder cancer	8.76e-05	0.0014	CcSEcCtD
Abiraterone—Urethral disorder—Doxorubicin—urinary bladder cancer	8.76e-05	0.0014	CcSEcCtD
Abiraterone—Mediastinal disorder—Epirubicin—urinary bladder cancer	8.7e-05	0.00139	CcSEcCtD
Abiraterone—Arrhythmia—Epirubicin—urinary bladder cancer	8.63e-05	0.00138	CcSEcCtD
Abiraterone—Vomiting—Cisplatin—urinary bladder cancer	8.49e-05	0.00136	CcSEcCtD
Abiraterone—Mental disorder—Epirubicin—urinary bladder cancer	8.46e-05	0.00135	CcSEcCtD
Abiraterone—Rash—Cisplatin—urinary bladder cancer	8.42e-05	0.00135	CcSEcCtD
Abiraterone—Dermatitis—Cisplatin—urinary bladder cancer	8.42e-05	0.00135	CcSEcCtD
Abiraterone—Diarrhoea—Etoposide—urinary bladder cancer	8.37e-05	0.00134	CcSEcCtD
Abiraterone—Anaemia—Methotrexate—urinary bladder cancer	8.3e-05	0.00133	CcSEcCtD
Abiraterone—Cardiac disorder—Doxorubicin—urinary bladder cancer	8.29e-05	0.00133	CcSEcCtD
Abiraterone—Angiopathy—Doxorubicin—urinary bladder cancer	8.11e-05	0.0013	CcSEcCtD
Abiraterone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	8.05e-05	0.00129	CcSEcCtD
Abiraterone—Arrhythmia—Doxorubicin—urinary bladder cancer	7.98e-05	0.00128	CcSEcCtD
Abiraterone—Cough—Methotrexate—urinary bladder cancer	7.84e-05	0.00125	CcSEcCtD
Abiraterone—Mental disorder—Doxorubicin—urinary bladder cancer	7.83e-05	0.00125	CcSEcCtD
Abiraterone—Vomiting—Etoposide—urinary bladder cancer	7.78e-05	0.00125	CcSEcCtD
Abiraterone—Anaemia—Epirubicin—urinary bladder cancer	7.77e-05	0.00124	CcSEcCtD
Abiraterone—Rash—Etoposide—urinary bladder cancer	7.72e-05	0.00123	CcSEcCtD
Abiraterone—Dermatitis—Etoposide—urinary bladder cancer	7.71e-05	0.00123	CcSEcCtD
Abiraterone—Myalgia—Methotrexate—urinary bladder cancer	7.65e-05	0.00122	CcSEcCtD
Abiraterone—Chest pain—Methotrexate—urinary bladder cancer	7.65e-05	0.00122	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	7.59e-05	0.00122	CcSEcCtD
Abiraterone—Discomfort—Methotrexate—urinary bladder cancer	7.56e-05	0.00121	CcSEcCtD
Abiraterone—Cough—Epirubicin—urinary bladder cancer	7.34e-05	0.00117	CcSEcCtD
Abiraterone—Infection—Methotrexate—urinary bladder cancer	7.28e-05	0.00117	CcSEcCtD
Abiraterone—Hypertension—Epirubicin—urinary bladder cancer	7.26e-05	0.00116	CcSEcCtD
Abiraterone—Anaemia—Doxorubicin—urinary bladder cancer	7.19e-05	0.00115	CcSEcCtD
Abiraterone—Chest pain—Epirubicin—urinary bladder cancer	7.16e-05	0.00115	CcSEcCtD
Abiraterone—Myalgia—Epirubicin—urinary bladder cancer	7.16e-05	0.00115	CcSEcCtD
Abiraterone—Skin disorder—Methotrexate—urinary bladder cancer	7.12e-05	0.00114	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	7.11e-05	0.00114	CcSEcCtD
Abiraterone—Discomfort—Epirubicin—urinary bladder cancer	7.07e-05	0.00113	CcSEcCtD
Abiraterone—Oedema—Epirubicin—urinary bladder cancer	6.86e-05	0.0011	CcSEcCtD
Abiraterone—Infection—Epirubicin—urinary bladder cancer	6.82e-05	0.00109	CcSEcCtD
Abiraterone—Cough—Doxorubicin—urinary bladder cancer	6.79e-05	0.00109	CcSEcCtD
Abiraterone—Hypertension—Doxorubicin—urinary bladder cancer	6.72e-05	0.00107	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.68e-05	0.00107	CcSEcCtD
Abiraterone—Skin disorder—Epirubicin—urinary bladder cancer	6.66e-05	0.00107	CcSEcCtD
Abiraterone—Insomnia—Methotrexate—urinary bladder cancer	6.63e-05	0.00106	CcSEcCtD
Abiraterone—Myalgia—Doxorubicin—urinary bladder cancer	6.62e-05	0.00106	CcSEcCtD
Abiraterone—Chest pain—Doxorubicin—urinary bladder cancer	6.62e-05	0.00106	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	6.58e-05	0.00105	CcSEcCtD
Abiraterone—Discomfort—Doxorubicin—urinary bladder cancer	6.54e-05	0.00105	CcSEcCtD
Abiraterone—Dyspnoea—Methotrexate—urinary bladder cancer	6.54e-05	0.00105	CcSEcCtD
Abiraterone—Dyspepsia—Methotrexate—urinary bladder cancer	6.45e-05	0.00103	CcSEcCtD
Abiraterone—Oedema—Doxorubicin—urinary bladder cancer	6.35e-05	0.00102	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.33e-05	0.00101	CcSEcCtD
Abiraterone—Fatigue—Methotrexate—urinary bladder cancer	6.32e-05	0.00101	CcSEcCtD
Abiraterone—Infection—Doxorubicin—urinary bladder cancer	6.31e-05	0.00101	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.25e-05	0.001	CcSEcCtD
Abiraterone—Insomnia—Epirubicin—urinary bladder cancer	6.2e-05	0.000993	CcSEcCtD
Abiraterone—Skin disorder—Doxorubicin—urinary bladder cancer	6.17e-05	0.000987	CcSEcCtD
Abiraterone—Dyspnoea—Epirubicin—urinary bladder cancer	6.12e-05	0.000979	CcSEcCtD
Abiraterone—Dyspepsia—Epirubicin—urinary bladder cancer	6.04e-05	0.000966	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.92e-05	0.000948	CcSEcCtD
Abiraterone—Fatigue—Epirubicin—urinary bladder cancer	5.91e-05	0.000947	CcSEcCtD
Abiraterone—Constipation—Epirubicin—urinary bladder cancer	5.87e-05	0.000939	CcSEcCtD
Abiraterone—Body temperature increased—Methotrexate—urinary bladder cancer	5.8e-05	0.000927	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.78e-05	0.000925	CcSEcCtD
Abiraterone—Insomnia—Doxorubicin—urinary bladder cancer	5.74e-05	0.000919	CcSEcCtD
Abiraterone—Dyspnoea—Doxorubicin—urinary bladder cancer	5.66e-05	0.000906	CcSEcCtD
Abiraterone—Dyspepsia—Doxorubicin—urinary bladder cancer	5.59e-05	0.000894	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.48e-05	0.000877	CcSEcCtD
Abiraterone—Fatigue—Doxorubicin—urinary bladder cancer	5.47e-05	0.000876	CcSEcCtD
Abiraterone—Constipation—Doxorubicin—urinary bladder cancer	5.43e-05	0.000869	CcSEcCtD
Abiraterone—Body temperature increased—Epirubicin—urinary bladder cancer	5.42e-05	0.000868	CcSEcCtD
Abiraterone—Asthenia—Methotrexate—urinary bladder cancer	5.26e-05	0.000842	CcSEcCtD
Abiraterone—Body temperature increased—Doxorubicin—urinary bladder cancer	5.02e-05	0.000803	CcSEcCtD
Abiraterone—Diarrhoea—Methotrexate—urinary bladder cancer	5.02e-05	0.000803	CcSEcCtD
Abiraterone—Asthenia—Epirubicin—urinary bladder cancer	4.92e-05	0.000788	CcSEcCtD
Abiraterone—Diarrhoea—Epirubicin—urinary bladder cancer	4.69e-05	0.000751	CcSEcCtD
Abiraterone—Vomiting—Methotrexate—urinary bladder cancer	4.66e-05	0.000746	CcSEcCtD
Abiraterone—Rash—Methotrexate—urinary bladder cancer	4.62e-05	0.00074	CcSEcCtD
Abiraterone—Dermatitis—Methotrexate—urinary bladder cancer	4.62e-05	0.000739	CcSEcCtD
Abiraterone—Asthenia—Doxorubicin—urinary bladder cancer	4.55e-05	0.000729	CcSEcCtD
Abiraterone—Vomiting—Epirubicin—urinary bladder cancer	4.36e-05	0.000698	CcSEcCtD
Abiraterone—Diarrhoea—Doxorubicin—urinary bladder cancer	4.34e-05	0.000695	CcSEcCtD
Abiraterone—Rash—Epirubicin—urinary bladder cancer	4.33e-05	0.000692	CcSEcCtD
Abiraterone—Dermatitis—Epirubicin—urinary bladder cancer	4.32e-05	0.000692	CcSEcCtD
Abiraterone—Vomiting—Doxorubicin—urinary bladder cancer	4.04e-05	0.000646	CcSEcCtD
Abiraterone—Rash—Doxorubicin—urinary bladder cancer	4e-05	0.00064	CcSEcCtD
Abiraterone—Dermatitis—Doxorubicin—urinary bladder cancer	4e-05	0.00064	CcSEcCtD
Abiraterone—ABCC1—Disease—SLC19A1—urinary bladder cancer	3.43e-05	0.000604	CbGpPWpGaD
Abiraterone—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.42e-05	0.000603	CbGpPWpGaD
Abiraterone—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	3.42e-05	0.000602	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—GSTP1—urinary bladder cancer	3.39e-05	0.000598	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—UGT2B7—urinary bladder cancer	3.37e-05	0.000595	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—NAT2—urinary bladder cancer	3.35e-05	0.000591	CbGpPWpGaD
Abiraterone—ABCC1—Disease—PRSS3—urinary bladder cancer	3.34e-05	0.000589	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.28e-05	0.000579	CbGpPWpGaD
Abiraterone—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	3.19e-05	0.000562	CbGpPWpGaD
Abiraterone—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	3.19e-05	0.000562	CbGpPWpGaD
Abiraterone—ABCC1—Disease—HDAC4—urinary bladder cancer	3.19e-05	0.000561	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—TYMS—urinary bladder cancer	3.16e-05	0.000556	CbGpPWpGaD
Abiraterone—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.14e-05	0.000554	CbGpPWpGaD
Abiraterone—ABCC1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.14e-05	0.000553	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—GSTM1—urinary bladder cancer	3.12e-05	0.00055	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—NCOR1—urinary bladder cancer	3.12e-05	0.00055	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.09e-05	0.000545	CbGpPWpGaD
Abiraterone—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	3.05e-05	0.000538	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—CYP4B1—urinary bladder cancer	3.04e-05	0.000536	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—GPX1—urinary bladder cancer	2.99e-05	0.000527	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—ERCC2—urinary bladder cancer	2.93e-05	0.000517	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—RRM2—urinary bladder cancer	2.89e-05	0.00051	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—SLC19A1—urinary bladder cancer	2.87e-05	0.000506	CbGpPWpGaD
Abiraterone—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	2.85e-05	0.000502	CbGpPWpGaD
Abiraterone—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.81e-05	0.000495	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—PRSS3—urinary bladder cancer	2.8e-05	0.000493	CbGpPWpGaD
Abiraterone—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	2.77e-05	0.000488	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—MTHFR—urinary bladder cancer	2.76e-05	0.000486	CbGpPWpGaD
Abiraterone—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	2.69e-05	0.000474	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—HPGDS—urinary bladder cancer	2.68e-05	0.000472	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—ENO2—urinary bladder cancer	2.68e-05	0.000472	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.66e-05	0.00047	CbGpPWpGaD
Abiraterone—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	2.62e-05	0.000461	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—GSTT1—urinary bladder cancer	2.6e-05	0.000458	CbGpPWpGaD
Abiraterone—ALB—Folate Metabolism—TNF—urinary bladder cancer	2.6e-05	0.000458	CbGpPWpGaD
Abiraterone—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.58e-05	0.000455	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.56e-05	0.000451	CbGpPWpGaD
Abiraterone—ABCC1—Disease—LIG1—urinary bladder cancer	2.53e-05	0.000446	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.52e-05	0.000444	CbGpPWpGaD
Abiraterone—ALB—Folate Metabolism—TP53—urinary bladder cancer	2.29e-05	0.000403	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.24e-05	0.000395	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—PPARG—urinary bladder cancer	2.24e-05	0.000394	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—TYMP—urinary bladder cancer	2.24e-05	0.000394	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—NQO1—urinary bladder cancer	2.16e-05	0.000381	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—CREBBP—urinary bladder cancer	2.15e-05	0.000379	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.15e-05	0.000378	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	2.13e-05	0.000375	CbGpPWpGaD
Abiraterone—ALB—Metabolism—GSTZ1—urinary bladder cancer	2.11e-05	0.000373	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.1e-05	0.000369	CbGpPWpGaD
Abiraterone—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	2.06e-05	0.000364	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—NAT2—urinary bladder cancer	2.02e-05	0.000356	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	2.01e-05	0.000355	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—NAT1—urinary bladder cancer	2.01e-05	0.000355	CbGpPWpGaD
Abiraterone—ALB—Metabolism—GSTO2—urinary bladder cancer	2e-05	0.000353	CbGpPWpGaD
Abiraterone—ALB—Metabolism—NAT1—urinary bladder cancer	2e-05	0.000353	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.98e-05	0.000349	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.97e-05	0.000347	CbGpPWpGaD
Abiraterone—ABCC1—Disease—ENO2—urinary bladder cancer	1.93e-05	0.00034	CbGpPWpGaD
Abiraterone—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	1.86e-05	0.000328	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	1.84e-05	0.000325	CbGpPWpGaD
Abiraterone—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.84e-05	0.000324	CbGpPWpGaD
Abiraterone—ALB—Metabolism—UGT2B7—urinary bladder cancer	1.83e-05	0.000323	CbGpPWpGaD
Abiraterone—ABCC1—Disease—RBX1—urinary bladder cancer	1.83e-05	0.000322	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.83e-05	0.000322	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—GSTP1—urinary bladder cancer	1.8e-05	0.000317	CbGpPWpGaD
Abiraterone—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	1.76e-05	0.000311	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—PTGS2—urinary bladder cancer	1.76e-05	0.00031	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—RRM2—urinary bladder cancer	1.74e-05	0.000308	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	1.74e-05	0.000308	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.74e-05	0.000307	CbGpPWpGaD
Abiraterone—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.71e-05	0.000302	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.7e-05	0.0003	CbGpPWpGaD
Abiraterone—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.69e-05	0.000298	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—TYMS—urinary bladder cancer	1.67e-05	0.000295	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	1.66e-05	0.000292	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—NCOR1—urinary bladder cancer	1.66e-05	0.000292	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—GSTM1—urinary bladder cancer	1.66e-05	0.000292	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	1.65e-05	0.000292	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—NAT1—urinary bladder cancer	1.65e-05	0.000292	CbGpPWpGaD
Abiraterone—ALB—Metabolism—CYP4B1—urinary bladder cancer	1.65e-05	0.000291	CbGpPWpGaD
Abiraterone—ABCC1—Disease—JAG1—urinary bladder cancer	1.64e-05	0.000289	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—HPGDS—urinary bladder cancer	1.62e-05	0.000285	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—ENO2—urinary bladder cancer	1.62e-05	0.000285	CbGpPWpGaD
Abiraterone—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	1.62e-05	0.000285	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.61e-05	0.000283	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—GPX1—urinary bladder cancer	1.59e-05	0.000279	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—IFNA2—urinary bladder cancer	1.57e-05	0.000277	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—GSTT1—urinary bladder cancer	1.57e-05	0.000276	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	1.57e-05	0.000276	CbGpPWpGaD
Abiraterone—ALB—Metabolism—SLC19A1—urinary bladder cancer	1.56e-05	0.000275	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—ERCC2—urinary bladder cancer	1.56e-05	0.000274	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.54e-05	0.000272	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—PTEN—urinary bladder cancer	1.53e-05	0.00027	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	1.53e-05	0.000269	CbGpPWpGaD
Abiraterone—ALB—Metabolism—PRSS3—urinary bladder cancer	1.52e-05	0.000268	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	1.51e-05	0.000267	CbGpPWpGaD
Abiraterone—ABCC1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.47e-05	0.000259	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—MTHFR—urinary bladder cancer	1.46e-05	0.000258	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—EP300—urinary bladder cancer	1.46e-05	0.000258	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	1.36e-05	0.00024	CbGpPWpGaD
Abiraterone—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	1.36e-05	0.000239	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—NQO1—urinary bladder cancer	1.3e-05	0.00023	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.29e-05	0.000227	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.26e-05	0.000223	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.25e-05	0.000221	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.22e-05	0.000216	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—TYMP—urinary bladder cancer	1.22e-05	0.000215	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.22e-05	0.000215	CbGpPWpGaD
Abiraterone—ALB—Metabolism—TYMP—urinary bladder cancer	1.21e-05	0.000214	CbGpPWpGaD
Abiraterone—ABCC1—Disease—NCOR1—urinary bladder cancer	1.19e-05	0.00021	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—PPARG—urinary bladder cancer	1.19e-05	0.000209	CbGpPWpGaD
Abiraterone—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.18e-05	0.000208	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.17e-05	0.000207	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.17e-05	0.000205	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.14e-05	0.000201	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—CREBBP—urinary bladder cancer	1.14e-05	0.000201	CbGpPWpGaD
Abiraterone—ABCC1—Disease—ERCC2—urinary bladder cancer	1.12e-05	0.000198	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—PLAU—urinary bladder cancer	1.12e-05	0.000197	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.1e-05	0.000195	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.1e-05	0.000194	CbGpPWpGaD
Abiraterone—ALB—Metabolism—NAT2—urinary bladder cancer	1.1e-05	0.000193	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—GSTP1—urinary bladder cancer	1.09e-05	0.000192	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.08e-05	0.000191	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.08e-05	0.000191	CbGpPWpGaD
Abiraterone—ABCC1—Disease—MTHFR—urinary bladder cancer	1.05e-05	0.000186	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.05e-05	0.000185	CbGpPWpGaD
Abiraterone—ABCC1—Disease—TERT—urinary bladder cancer	1.05e-05	0.000185	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—TYMS—urinary bladder cancer	1.01e-05	0.000178	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1e-05	0.000177	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—GSTM1—urinary bladder cancer	9.98e-06	0.000176	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—NCOR1—urinary bladder cancer	9.98e-06	0.000176	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	9.89e-06	0.000174	CbGpPWpGaD
Abiraterone—ABCC1—Disease—FGFR3—urinary bladder cancer	9.64e-06	0.00017	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—GPX1—urinary bladder cancer	9.56e-06	0.000169	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—RRM2—urinary bladder cancer	9.53e-06	0.000168	CbGpPWpGaD
Abiraterone—ALB—Metabolism—RRM2—urinary bladder cancer	9.47e-06	0.000167	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—ERCC2—urinary bladder cancer	9.39e-06	0.000165	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—PTGS2—urinary bladder cancer	9.33e-06	0.000164	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—CREBBP—urinary bladder cancer	9.2e-06	0.000162	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—IGF1—urinary bladder cancer	9.09e-06	0.00016	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—NAT2—urinary bladder cancer	9.06e-06	0.00016	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	8.91e-06	0.000157	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	8.82e-06	0.000156	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—ENO2—urinary bladder cancer	8.82e-06	0.000156	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—MTHFR—urinary bladder cancer	8.82e-06	0.000156	CbGpPWpGaD
Abiraterone—ALB—Metabolism—ENO2—urinary bladder cancer	8.77e-06	0.000155	CbGpPWpGaD
Abiraterone—ALB—Metabolism—HPGDS—urinary bladder cancer	8.77e-06	0.000155	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.77e-06	0.000155	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.72e-06	0.000154	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	8.56e-06	0.000151	CbGpPWpGaD
Abiraterone—ALB—Metabolism—GSTT1—urinary bladder cancer	8.51e-06	0.00015	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.43e-06	0.000149	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	8.41e-06	0.000148	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.38e-06	0.000148	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—RHOA—urinary bladder cancer	8.33e-06	0.000147	CbGpPWpGaD
Abiraterone—ABCC1—Disease—CREBBP—urinary bladder cancer	8.21e-06	0.000145	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	8.2e-06	0.000144	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—PTEN—urinary bladder cancer	8.14e-06	0.000143	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.97e-06	0.00014	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—RRM2—urinary bladder cancer	7.82e-06	0.000138	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—EP300—urinary bladder cancer	7.76e-06	0.000137	CbGpPWpGaD
Abiraterone—ABCC1—Disease—RHOA—urinary bladder cancer	7.42e-06	0.000131	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—ENO2—urinary bladder cancer	7.24e-06	0.000128	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	7.24e-06	0.000128	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—PPARG—urinary bladder cancer	7.16e-06	0.000126	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—NQO1—urinary bladder cancer	7.11e-06	0.000125	CbGpPWpGaD
Abiraterone—ALB—Metabolism—NQO1—urinary bladder cancer	7.07e-06	0.000125	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	7.03e-06	0.000124	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—IL2—urinary bladder cancer	6.99e-06	0.000123	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.9e-06	0.000122	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—CREBBP—urinary bladder cancer	6.87e-06	0.000121	CbGpPWpGaD
Abiraterone—ABCC1—Disease—ERBB2—urinary bladder cancer	6.87e-06	0.000121	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.86e-06	0.000121	CbGpPWpGaD
Abiraterone—ABCC1—Disease—PTGS2—urinary bladder cancer	6.72e-06	0.000118	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	6.55e-06	0.000115	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—EP300—urinary bladder cancer	6.27e-06	0.000111	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—SRC—urinary bladder cancer	6.1e-06	0.000107	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.02e-06	0.000106	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.98e-06	0.000105	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	5.93e-06	0.000105	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	5.93e-06	0.000104	CbGpPWpGaD
Abiraterone—ALB—Metabolism—GSTP1—urinary bladder cancer	5.9e-06	0.000104	CbGpPWpGaD
Abiraterone—ABCC1—Disease—CDKN1A—urinary bladder cancer	5.87e-06	0.000104	CbGpPWpGaD
Abiraterone—ABCC1—Disease—PTEN—urinary bladder cancer	5.86e-06	0.000103	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—NQO1—urinary bladder cancer	5.84e-06	0.000103	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.74e-06	0.000101	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.71e-06	0.000101	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—PTGS2—urinary bladder cancer	5.63e-06	9.92e-05	CbGpPWpGaD
Abiraterone—ABCC1—Disease—EP300—urinary bladder cancer	5.59e-06	9.85e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—TYMS—urinary bladder cancer	5.52e-06	9.72e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—TYMS—urinary bladder cancer	5.48e-06	9.67e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	5.45e-06	9.61e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	5.45e-06	9.61e-05	CbGpPWpGaD
Abiraterone—ABCC1—Disease—SRC—urinary bladder cancer	5.44e-06	9.58e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—GSTM1—urinary bladder cancer	5.42e-06	9.56e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—NCOR1—urinary bladder cancer	5.42e-06	9.56e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—GPX1—urinary bladder cancer	5.22e-06	9.2e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—GPX1—urinary bladder cancer	5.19e-06	9.15e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	5.13e-06	9.04e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.11e-06	9.02e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—ERCC2—urinary bladder cancer	5.1e-06	8.98e-05	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—KRAS—urinary bladder cancer	5.05e-06	8.9e-05	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—PTEN—urinary bladder cancer	4.91e-06	8.65e-05	CbGpPWpGaD
Abiraterone—ABCC1—Disease—MYC—urinary bladder cancer	4.87e-06	8.59e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	4.87e-06	8.59e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	4.82e-06	8.49e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—MTHFR—urinary bladder cancer	4.79e-06	8.45e-05	CbGpPWpGaD
Abiraterone—ABCC1—Disease—EGFR—urinary bladder cancer	4.76e-06	8.4e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.74e-06	8.35e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.74e-06	8.35e-05	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—EP300—urinary bladder cancer	4.68e-06	8.25e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.59e-06	8.1e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—TYMS—urinary bladder cancer	4.53e-06	7.98e-05	CbGpPWpGaD
Abiraterone—ABCC1—Disease—KRAS—urinary bladder cancer	4.5e-06	7.93e-05	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—TP53—urinary bladder cancer	4.49e-06	7.91e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	4.48e-06	7.89e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	4.48e-06	7.89e-05	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—HRAS—urinary bladder cancer	4.29e-06	7.56e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	4.29e-06	7.56e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	4.21e-06	7.42e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.96e-06	6.97e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—PPARG—urinary bladder cancer	3.91e-06	6.89e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—PPARG—urinary bladder cancer	3.88e-06	6.85e-05	CbGpPWpGaD
Abiraterone—ABCC1—Disease—HRAS—urinary bladder cancer	3.83e-06	6.74e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.82e-06	6.73e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	3.75e-06	6.62e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—CREBBP—urinary bladder cancer	3.73e-06	6.58e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	3.21e-06	5.65e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.18e-06	5.61e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.08e-06	5.43e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	3.07e-06	5.42e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—PTGS2—urinary bladder cancer	3.06e-06	5.39e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.96e-06	5.22e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.93e-06	5.16e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.93e-06	5.16e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.8e-06	4.94e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.75e-06	4.85e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—PTEN—urinary bladder cancer	2.68e-06	4.73e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—PTEN—urinary bladder cancer	2.67e-06	4.7e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.59e-06	4.56e-05	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—EP300—urinary bladder cancer	2.56e-06	4.51e-05	CbGpPWpGaD
Abiraterone—ALB—Metabolism—EP300—urinary bladder cancer	2.54e-06	4.48e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.52e-06	4.45e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.2e-06	3.88e-05	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.1e-06	3.7e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.1e-06	3.7e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.01e-06	3.55e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.65e-06	2.91e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.44e-06	2.54e-05	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.37e-06	2.42e-05	CbGpPWpGaD
